MIAMI--(BUSINESS WIRE)--H.I.G. Capital, a leading Miami-based private equity firm, announced today the recapitalization of The Harvard Drug Group, L.L.C. (Harvard Drug). With approximately $400 million in revenues, Harvard Drug, based in Livonia, Michigan, is the second largest generics-focused pharmaceutical distributor in the United States. Harvard Drug supplies generic and branded pharmaceuticals to over 6,000 retail customers, which include independent, regional and national pharmacies. Harvard Drug also services institutional clients through its “Major” label of generic drugs, which has a product offering of over 1,000 prescription pharmaceuticals, over-the-counter (“OTC”) products, vitamins and unit-of use products. Harvard Drug’s institutional clients include hospital central-purchasing agents, long-term-care facilities, and government clients. Founded in 1967, Harvard Drug benefits from long-standing relationships with key pharmaceutical manufacturers.
